36
Views
7
CrossRef citations to date
0
Altmetric
Anatomical Pathology

Expression and prognostic significance of SIRT1 in ovarian epithelial tumours

, , , , , , , , , & show all
Pages 366-371 | Received 13 Jan 2008, Accepted 03 Jun 2008, Published online: 06 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (7)

Bin Zhao, Xin Li, Liangfu Zhou, Ye Wang & Peng Shang. (2019) SIRT1: a potential tumour biomarker and therapeutic target. Journal of Drug Targeting 27:10, pages 1046-1052.
Read now
Luis Filipe Costa-Machado & Pablo J. Fernandez-Marcos. (2019) The sirtuin family in cancer. Cell Cycle 18:18, pages 2164-2196.
Read now
Kotaro Kiga, Yoko Fukuda-Yuzawa, Masanobu Tanabe, Shoji Tsuji, Chihiro Sasakawa & Taro Fukao. (2014) Comprehensive silencing of target-sharing microRNAs is a mechanism for SIRT1 overexpression in cancer. RNA Biology 11:11, pages 1347-1354.
Read now
Hongfeng Yuan, Leila Su & Wen Yong Chen. (2013) The emerging and diverse roles of sirtuins in cancer: a clinical perspective. OncoTargets and Therapy 6, pages 1399-1416.
Read now
Ramez N Eskander & Krishnansu S Tewari. (2013) Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clinical Pharmacology: Advances and Applications 5, pages 55-61.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.